Quantbot Technologies LP Buys 1,984 Shares of Eli Lilly and Company (NYSE:LLY)

Quantbot Technologies LP lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 52.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 5,741 shares of the company's stock after buying an additional 1,984 shares during the quarter. Quantbot Technologies LP's holdings in Eli Lilly and Company were worth $4,432,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of LLY. Highline Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 80.0% during the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after acquiring an additional 20 shares during the period. Kovitz Investment Group Partners LLC boosted its stake in Eli Lilly and Company by 117.1% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 46,132 shares of the company's stock valued at $41,000 after purchasing an additional 24,879 shares during the period. FPC Investment Advisory Inc. grew its holdings in Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after buying an additional 43 shares in the last quarter. Compass Financial Services Inc bought a new position in Eli Lilly and Company during the 4th quarter worth $50,000. Finally, Fiduciary Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $58,000. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on LLY. Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a research note on Thursday, March 6th. Citigroup decreased their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research report on Friday, January 17th. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Finally, Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a report on Thursday, January 16th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1,009.72.

Remove Ads

Eli Lilly and Company Price Performance

LLY stock traded down $25.51 during trading on Wednesday, reaching $826.84. 2,561,764 shares of the company were exchanged, compared to its average volume of 3,149,062. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company has a market capitalization of $783.98 billion, a price-to-earnings ratio of 70.61, a P/E/G ratio of 1.40 and a beta of 0.34. The company has a 50-day moving average of $839.56 and a two-hundred day moving average of $837.61.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has authorized a share buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's leadership believes its stock is undervalued.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.